Ionis Pharmaceuticals, Inc. Stock News

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: Raymond James 46th Annual Institutional Investors Conference on Tuesday, March 4, 2025 TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025 Leerink Partners Global Healthcare Conference 2025 on Tu...

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it will present additional data from the pivotal Phase 3 OASIS and OASISplus studies, as well as three year data from the Phase 2 open-label extension (OLE) study of donidalorsen, the company's investigational RNA-targeted prophylactic medicine for hereditary angioedema (HAE). Results will be pres...

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Q4 2024 Earnings Conference Call February 19, 2025 11:30 AM ET Company Participants Wade Walke - Senior Vice President of Investor Relations Brett Monia - Chief Executive Officer Kyle Jenne - Chief Global Product Strategy Officer Richard Geary - Chief Development Officer Elizabeth Hougen - Chief Financial Officer Eugene Schneider - Chief Clinical Devel...

Ionis Pharmaceuticals' Q4 earnings beat expectations, but guidance for 2025 was slightly below consensus, leading to a HOLD rating pending further catalysts. TRYNGOLZA's approval for FCS is promising, but expansion into the larger sHTG market by 2025 is crucial for the company to reach profitability and satisfy analyst's estimates. Ionis has a strong cash position and a robust pipeline of over ...

Ionis Pharmaceuticals (IONS 0.44%), a leader in RNA-targeted drug discovery and development, announced its earnings results for the fourth quarter on Feb. 19. The report revealed that Ionis outperformed analysts' top-line expectations with revenue of $227 million compared to the anticipated $135 million.

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the “Company”) today reported financial results for the fourth quarter and full year ended December 31, 2024. “With the recent launch of our first independent medicine, TRYNGOLZA for familial chylomicronemia syndrome, Ionis has begun a new chapter as a fully integrated commercial-stage biotechnology company,” said Br...

CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, February 19th at 11:30 a.m. Eastern Time to discuss its fourth quarter and full year 2024 financial results. The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the ...

The market will grow as a result of the increasing incidence of amyloidosis, technological advancements in diagnostics, increased focus on rare diseases, improved healthcare infrastructure, increased awareness and support programs, and strategic alliances and collaborations. The market will grow as a result of the increasing incidence of amyloidosis, technological advancements in diagnostics, i...